Consensus Scholar Rock Holding Corporation

Stocks

SRRK

US80706P1030

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			5-day change	1st Jan Change
44.18 ^USD	-1.14%		-0.27%	+0.30%

06-11	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-09	Scholar Rock Holding Corporation Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 10:00 AM

Evolution of the Average Target: Scholar Rock Holding Corporation

Evolution of the Target Price: Scholar Rock Holding Corporation

Changes in Analyst Recommendations: Scholar Rock Holding Corporation

6bed1dfcb1.qS-GKYtMyulFVlr74Sv7TchMnNtw5Wk0jlk8EEBa4G0.7Gqra-kImZM0YSLIkUOjGZA7yZIXtzkNzAFlZRhrlCH6Q9Fd4Aa-u3BuOQ~4809bca3520f07f8eaac7a0ce0df3c9a

Analysts' recommendations: Scholar Rock Holding Corporation

04-21	Canaccord Genuity Initiates Scholar Rock at Buy With $62 Price Target	MT
03-31	Wedbush Adjusts Price Target on Scholar Rock Holding to $58 From $56, Maintains Outperform Rating	MT
03-04	Truist Raises Price Target on Scholar Rock Holding to $55 From $44, Keeps Buy Rating	MT
03-03	Wedbush Adjusts Price Target on Scholar Rock to $56 From $50, Maintains Outperform Rating	MT
01-07	UBS Initiates Scholar Rock Holding at Buy With $60 Price Target	MT
11-14	Wedbush Adjusts Pt on Scholar Rock Holding to $50 From $43, Maintains Outperform Rating	MT
23/09/25	HC Wainwright Adjusts Price Target on Scholar Rock Holding to $44 From $50, Maintains Buy Rating	MT
23/09/25	Scholar Rock's Apitegromab Approval Still Likely Despite Delay, Wedbush Says	MT
17/09/25	Barclays Initiates Scholar Rock at Overweight With $45 Price Target	MT
15/09/25	Leerink Partners Initiates Scholar Rock at Outperform With $51 Price Target	MT
06/08/25	Biopharma Scholar Rock Q2 net loss widens, no revenue	RE
18/07/25	Truist Raises Price Target on Scholar Rock Holding to $54 From $45, Keeps Buy Rating	MT
17/07/25	Cantor Fitzgerald Initiates Coverage on Scholar Rock With Overweight Rating	MT
27/02/25	Wedbush Adjusts Scholar Rock Price Target to $50 From $47, Maintains Outperform Rating	MT
25/11/24	Wedbush Raises Price Target on Scholar Rock to $47 From $40, Maintains Outperform Rating	MT
25/11/24	Truist Securities Adjusts Price Target on Scholar Rock to $45 From $36, Maintains Buy Rating	MT
12/11/24	Wedbush Raises Price Target on Scholar Rock to $40 From $37, Maintains Outperform Rating	MT
08/10/24	Scholar Rock's Spinal Muscular Atrophy Drug Plans for Children Under 2 Could Broaden Patient Group, Truist Says	MT
07/10/24	Scholar Rock's Phase 3 Apitegromab Trial in Spinal Muscular Atrophy Meets Primary Endpoint	MT
07/10/24	Wedbush Raises Price Target on Scholar Rock Holding to $27 From $25, Keeps Outperform Rating	MT
07/10/24	Truist Raises Price Target on Scholar Rock Holding to $36 From $20, Keeps Buy Rating	MT
27/09/24	Wedbush Raises Price Target on Scholar Rock to $25 From $23, Keeps Outperform Rating	MT
13/06/24	BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating	MT
28/03/24	Raymond James Initiates Scholar Rock With Strong Buy Rating, $30 Price Target	MT
25/10/23	Jefferies Upgrades Scholar Rock to Buy From Hold, Adjusts Price Target to $20 From $7	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SCHOLAR ROCK HOLDING CORPORATION					+34.25%
	ARGENX SE					+8.05%
	WUXI APPTEC CO., LTD.					+46.39%
	BIONTECH SE					+36.71%
	INSMED INCORPORATED					+101.96%
	WUXI BIOLOGICS (CAYMAN) INC.					+50.93%
	GENMAB A/S					+42.87%
	EXELIXIS, INC.					-7.77%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+31.9%
	PHARMAESSENTIA CORPORATION					-14.59%
	Average					+33.07%
	Weighted average by Cap.					+33.46%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.18USD

Average target price

59.31USD

Spread / Average Target

+34.25%

High Price Target

70.00USD

Spread / Highest target

+58.44%

Low Price Target

48.00USD

Spread / Lowest Target

+8.65%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Canaccord Genuity
Wedbush
Truist Securities
UBS
HC Wainwright
Barclays
Leerink Partners
Cantor Fitzgerald
BMO Capital
Raymond James
Jefferies & Co.
Piper Sandler
JPMorgan Chase